ArticleCirculation2015
Misdiagnosis of Myocardial Infarction Related to Limitations of the Current Regulatory Approach to Define Clinical Decision Values for Cardiac Troponin.
Article in Circulation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Advantageous Predictors of Acute Coronary Syndromes Evaluation (APACE) Study
Trial of Switching High-sensitivity Cardiac Troponin Assays in Suspected Acute Coronary Syndrome: an Interrupted Time Series Analysis (TWITCH-ED Study)
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 135 citations in OpenAlex.
- "Low-to-moderate arsenic exposure: a global systematic review of cardiovascular disease risks".Environmental health : a global access science source · 2025Pooled it
- Pooled it
- Mortality risk prediction of high-sensitivity C-reactive protein in suspected acute coronary syndrome: A cohort study.PLoS medicine · 2022Trial
- Mechanism study of miR-324-3p driving myocardial infarction progression through regulation of myocardial inflammation.Journal of cardiothoracic surgery · 2026Article
- Impact of multiple stent implantation on periprocedural myocardial infarction in patients undergoing planned pci in a clinically stable setting: insights from a single-centre cohort study.BMC cardiovascular disorders · 2026Article
- Elevated Cardiac Troponin in Non-Cardiac Conditions Unrelated to Acute Myocardial Infarction.International journal of molecular sciences · 2025Review
- The Misdiagnosis Tracker: Enhancing Diagnostic Reasoning Through Cognitive Bias Awareness and Error Analysis.Journal of clinical medicine · 2025Article
- Possible Misdiagnosis of Myocardial Infarction Using Regulatory-Approved and Close-to-Bioequivalent Upper Limits of Normal for Cardiac Troponin.Journal of the American Heart Association · 2025Observational
- Copeptin in Acute Myocardial Infarction: Is There a Role in the Era of High-Sensitivity Troponins?Journal of cardiovascular development and disease · 2025Review
- Do we need internal medicine specialists in physical therapy? Recognizing the need for updating the clinical practice paradigm.Frontiers in rehabilitation sciences · 2025Article
- Improved diagnostic performance of high-sensitivity cardiac troponins in muscle dystrophies using comprehensive definition criteria for cardiac involvement: A longitudinal study on 35 patients.European journal of neurology · 2024Article
- Validation and correlation of high-sensitive troponin I and troponin T in the emergency department.BMC cardiovascular disorders · 2024Article
- Association of Cardiac Troponin T With Coronary Atherosclerosis in Asymptomatic Primary Prevention People With HIV.JACC. Advances · 2024Article
- Article
- Impact of the ESC Cardio-Oncology Guidelines Biomarker Criteria on Incidence of Cancer Therapy-Related Cardiac Dysfunction.JACC. CardioOncology · 2024Article
- Combining glucose and high-sensitivity cardiac troponin in the early diagnosis of acute myocardial infarction.Scientific reports · 2023Article
- Machine learning for diagnosis of myocardial infarction using cardiac troponin concentrations.Nature medicine · 2023Article
- Prognostic values of high sensitivity cardiac troponin T and I for long-term mortality in hemodialysis patients.Scientific reports · 2022Article
- Skeletal Muscle Disorders: A Noncardiac Source of Cardiac Troponin T.Circulation · 2022Article
- Retrospective validation of a machine learning clinical decision support tool for myocardial infarction risk stratification.Healthcare technology letters · 2021Article
Corrections and comments
- Commented on by
Authors and funding
23 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMisdiagnosis of acute myocardial infarction (AMI) may significantly harm patients and may result from inappropriate clinical decision values (CDVs) for cardiac troponin (cTn) owing to limitations in the current regulatory process. METHODS AND
resultsIn an international, prospective, multicenter study, we quantified the incidence of inconsistencies in the diagnosis of AMI using fully characterized and clinically available high-sensitivity (hs) cTn assays (hs-cTnI, Abbott; hs-cTnT, Roche) among 2300 consecutive patients with suspected AMI. We hypothesized that the approved CDVs for the 2 assays are not biologically equivalent and might therefore contribute to inconsistencies in the diagnosis of AMI. Findings were validated by use of sex-specific CDVs and parallel measurements of other hs-cTnI assays. AMI was the adjudicated diagnosis in 473 patients (21%). Among these, 86 patients (18.2%) had inconsistent diagnoses when the approved uniform CDV was used. When sex-specific CDVs were used, 14.1% of female and 22.7% of male AMI patients had inconsistent diagnoses. Using biologically equivalent CDV reduced inconsistencies to 10% (P<0.001). These findings were confirmed with parallel measurements of other hs-cTn assays. The incidence of inconsistencies was only 7.0% for assays with CDVs that were nearly biologically equivalent. Patients with inconsistent AMI had long-term mortality comparable to that of patients with consistent diagnoses (P=NS) and a trend toward higher long-term mortality than patients diagnosed with unstable angina (P=0.05).
conclusionsCurrently approved CDVs are not biologically equivalent and contribute to major inconsistencies in the diagnosis of AMI. One of 5 AMI patients will receive a diagnosis other than AMI if managed with the alternative hs-cTn assay. CLINICAL
trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT00470587.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.